|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
10 |
21 |
27 |
56 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2011-05-04 |
4 |
S |
$25.84 |
$70,547 |
D/D |
(2,700) |
88,193 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2011-05-04 |
4 |
OE |
$9.86 |
$9,860 |
D/D |
1,000 |
90,893 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2011-05-03 |
4 |
S |
$26.68 |
$134,266 |
D/D |
(5,000) |
89,893 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2011-05-03 |
4 |
OE |
$9.86 |
$29,580 |
D/D |
3,000 |
94,893 |
|
- |
|
Aselage Steve |
EVP, Chief Business Officer |
|
2011-05-03 |
4 |
S |
$27.15 |
$279,895 |
D/D |
(10,311) |
31,478 |
|
- |
|
Aselage Steve |
EVP, Chief Business Officer |
|
2011-05-03 |
4 |
OE |
$17.33 |
$178,690 |
D/D |
10,311 |
41,789 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2011-05-02 |
4 |
AS |
$27.09 |
$41,452 |
D/D |
(1,530) |
27,901 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2011-04-29 |
4 |
A |
$11.64 |
$16,838 |
D/D |
1,447 |
69,160 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2011-04-29 |
4 |
A |
$13.23 |
$21,426 |
D/D |
1,620 |
24,455 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2011-04-29 |
4 |
A |
$11.64 |
$18,223 |
D/D |
1,566 |
28,376 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2011-04-29 |
4 |
A |
$11.64 |
$17,466 |
D/D |
1,501 |
2,613 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2011-04-29 |
4 |
A |
$11.64 |
$21,249 |
D/D |
1,826 |
91,893 |
|
- |
|
Aselage Steve |
EVP, Chief Business Officer |
|
2011-04-29 |
4 |
A |
$11.64 |
$18,583 |
D/D |
1,597 |
31,478 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2011-04-29 |
4 |
A |
$11.64 |
$17,805 |
D/D |
1,530 |
29,431 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-04-25 |
4 |
S |
$26.35 |
$43,377 |
D/D |
(1,646) |
14,243 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-04-25 |
4 |
OE |
$14.39 |
$25,815 |
D/D |
1,646 |
15,889 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2011-04-20 |
4 |
S |
$27.00 |
$355,455 |
D/D |
(13,165) |
22,835 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2011-04-20 |
4 |
OE |
$11.05 |
$55,250 |
D/D |
5,000 |
36,000 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-04-13 |
4 |
S |
$26.00 |
$18,408 |
D/D |
(708) |
14,243 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-04-13 |
4 |
OE |
$17.33 |
$12,314 |
D/D |
708 |
14,951 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2011-04-13 |
4 |
AS |
$26.50 |
$100,700 |
D/D |
(3,800) |
27,901 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2011-04-13 |
4 |
OE |
$11.74 |
$44,612 |
D/D |
3,800 |
31,701 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2011-04-01 |
4 |
S |
$25.45 |
$63,626 |
D/D |
(2,500) |
31,000 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2011-04-01 |
4 |
OE |
$11.05 |
$27,625 |
D/D |
2,500 |
33,500 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2011-03-22 |
4 |
S |
$23.42 |
$21,970 |
D/D |
(938) |
14,243 |
|
- |
|
1312 Records found
|
|
Page 29 of 53 |
|
|